Gilead takes over German virology biotech MYR and lands hepatitis D treatment approved in Europe – FierceBiotech
Gilead takes over German virology biotech MYR and lands hepatitis D treatment approved in Europe – FierceBiotech
Gilead Sciences is all about cancer these days, right? Well, no: the early clearance of remdesivir in COVID-19 has seen its infectious disease credentials reinstated this year, and now it will double down with a buyout deal from MYR Pharmaceuticals. Little-known German biotechnology has worked on a first-rate drug against the chronic hepatitis delta virus […]
The post Gilead takes over German…